COVID-19, ARDS
Conditions
Interventions
The administration of inhaled isoflurane for sedation, compared to intravenous sedation. In this pilot study, patients will intermittent receive inhaled or intravenous sedation, according to the rando
Sponsors
University Medical Center Utrecht
Eligibility
Inclusion criteria
Inclusion criteria: • Confirmed or suspected COVID-19 • Respiratory failure requiring mechanical ventilation through an endotracheal tube • Ventilation using a ventilator that is capable of delivering sevoflurane or isoflurane • >18 years of age
Exclusion criteria
Exclusion criteria: • Suspected or proven intracranial hypertension • Tidal volume (6 ml/kg predicted body weight [PBW]) less than 250 ml • Malignant hyperthermia history, or family risk factors • History of long QT syndrome • Severe liver failure • Previous kidney or liver transplantation • Requirement for extracorporeal mechanical respiratory or circulatory support
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in PaO2/FiO2 (P/F) ratio, oxygenation index, and ventilation parameters | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety endpoints: Haemodynamic stability, acute liver injury, acute kidney injury Secondary endpoints: In-hospital mortality, P/F ratio and oxygenation index at various time points, time to extubation, length of stay in the ICU, length of stay in the hospital, major complications (sepsis, renal failure, MI, stroke, requirement for ECMO, delirium, atrial fibrillation, and myocardial injury). | — |
Contacts
Public ContactJan Dieleman
UMC Utrecht
Outcome results
None listed